Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation.

Peter Liebisch, MD, Christian Straka, MD, Astrid Wimmer, MD, Christiane Wendl, MD, Axel Hinke, Stefan Ibach, Hartmut Döhner

Blood (2007) 110 (11): 992.

https://doi.org/10.1182/blood.V110.11.992.992

Published: 2007

Journal Articles

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Jochen Greiner, MD, Krzysztof Giannopoulos, MD, Li Li, MD, Peter Liebisch, MD, Christiane Wendl, MD, Jinfei Chen, MD, Mark Ringhoffer, MD, Phillipe Guillaume, PhD, Gerd Ritter, PhD, Hartmut Doehner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 2781.

https://doi.org/10.1182/blood.V106.11.2781.2781

Published: 2005

Journal Articles

Gains on Chromosome Arm 9q Represent a Novel and Independent Marker of Adverse Prognosis in Multiple Myeloma Patients Receiving Upfront High-Dose Chemotherapy and Autologous Stem Cell Transplantation.

Peter Liebisch, MD, Axel Benner, Kathrin Tschajka, Christiane Wendl, MD, Hartmut Goldschmidt, MD, Hartmut Döhner, MD

Blood (2005) 106 (11): 1559.

https://doi.org/10.1182/blood.V106.11.1559.1559

Published: 2005

Journal Articles

Automated Screening for Genomic Imbalances in Multiple Myeloma Using Microarray-Based Comparative Genomic Hybridization (mCGH).

Christiane Wendl, MD, Bernhard Radlwimmer, PhD, Swen Wessendorf, MD, Carsten Schwaenen, MD, Hartmut Döhner, MD, Peter Lichter, MD, Peter Liebisch, MD

Blood (2005) 106 (11): 499.

https://doi.org/10.1182/blood.V106.11.499.499

Published: 2005

Journal Articles

The Molecular Cytogenetic Analysis of MGUS Provides Additional Evidence for a Novel, 14q-Translocation Independent Pathogenetic Pathway in Clonal Plasma Cell Disorders.

Peter Liebisch, MD, Meike Kirschenlohr, Christiane Wendl, MD, Hartmut Dohner, MD

Blood (2004) 104 (11): 3648.

https://doi.org/10.1182/blood.V104.11.3648.3648

Published: 2004

Journal Articles

Gains on Chromosome Band 9q34 Could Represent a Novel Independent Prognostic Marker in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Stem Cell Transplantation.

Peter Liebisch, MD, Hartmut Goldschmidt, MD, Kathrin Tschajka, Christiane Wendl, MD, Axel Benner, MD, Hartmut Dohner, MD

Blood (2004) 104 (11): 1100.

https://doi.org/10.1182/blood.V104.11.1100.1100

Published: 2004

NARROW

Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation.

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Gains on Chromosome Arm 9q Represent a Novel and Independent Marker of Adverse Prognosis in Multiple Myeloma Patients Receiving Upfront High-Dose Chemotherapy and Autologous Stem Cell Transplantation.

Automated Screening for Genomic Imbalances in Multiple Myeloma Using Microarray-Based Comparative Genomic Hybridization (mCGH).

The Molecular Cytogenetic Analysis of MGUS Provides Additional Evidence for a Novel, 14q-Translocation Independent Pathogenetic Pathway in Clonal Plasma Cell Disorders.

Gains on Chromosome Band 9q34 Could Represent a Novel Independent Prognostic Marker in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation.

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Gains on Chromosome Arm 9q Represent a Novel and Independent Marker of Adverse Prognosis in Multiple Myeloma Patients Receiving Upfront High-Dose Chemotherapy and Autologous Stem Cell Transplantation.

Automated Screening for Genomic Imbalances in Multiple Myeloma Using Microarray-Based Comparative Genomic Hybridization (mCGH).

The Molecular Cytogenetic Analysis of MGUS Provides Additional Evidence for a Novel, 14q-Translocation Independent Pathogenetic Pathway in Clonal Plasma Cell Disorders.

Gains on Chromosome Band 9q34 Could Represent a Novel Independent Prognostic Marker in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only